Unlock instant, AI-driven research and patent intelligence for your innovation.

Novel tnfr agonists and uses thereof

A kind of technology of agonist and use, applied in the field of use

Inactive Publication Date: 2019-09-27
ICHNOS SCI SA
View PDF21 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Other studies confirmed that the frequency of Treg cells in draining lymph nodes did not change even at later time points after anti-OX40 treatment, so this effect may be localized to the tumor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel tnfr agonists and uses thereof
  • Novel tnfr agonists and uses thereof
  • Novel tnfr agonists and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0121] Production and screening of mouse anti-human OX40 antibody

[0122] To generate recombinant human OX40-his protein, the extracellular region of human TNFRSF4 (amino acids 1-214 shown in SEQ ID NO: 1) was amplified by PCR and a 3'GSG-6xHis linker and restriction sites were added for cloning. The PCR product was subsequently cloned into the modified pcDNA3.1(-) plasmid described above. This recombinant plasmid allows expression of human OX40-his protein in mammalian cells and secretion into the cell culture medium driven by the native signal peptide of human TNFRSF4. For protein production, use jetPEI TM Transfection reagent (Polyplus-transfection S.A., Strasbourg, France; Distributor: Brunschwig, Basel, Switzerland) transfects the recombinant vector into suspension-adapted HEK 293 cells (ATCC No. CRL 1573). Cell culture supernatants were collected 5 days after transfection and used in Ni operated on an FPLC system (GE Healthcare Europe GmbH, Glattbrugg, Switzerland) ...

Embodiment 2

[0132] Cloning and sequencing of the VH and VL chains of anti-OX40 antibodies from hybridoma cells

[0133] For each positively selected hybridoma, total RNA was prepared, reverse transcribed into cDNA, and the VH and VL genes were separately amplified by PCR. Ligation of these PCR products into a rescue-vector (pDrive vector; QIAGEN AG, Hombrechtikon, Switzerland; Cat.No. 231124) allows DNA sequencing of individual PCR products and determination of the monoclonal or polyclonal nature of selected hybridomas. sex. This vector allows blue / white selection on LB-agar plates containing IPTG and X-gal (colony without insert is blue because LacZa-peptide degrades X-gal). Recombinant plasmids from positive (white) bacterial clones were prepared and sequenced using standard DNA sequencing primers specific to the vector backbone (M13rev, M13fwd, T7 or SP6). Finally, the DNA sequence is subcloned into an expression vector for recombinant expression of the target antibody in mammalian c...

Embodiment 3

[0166] Biological characteristics of anti-human OX40 antibody

[0167] OX40 specific antibody detection ELISA

[0168] Antibody titer, specificity, and production of hybridoma and recombinant antibody candidates were determined by direct ELISA. Briefly, 96-well microtiter plates (Costar USA, distributor VWR AG, Nyon, Switzerland) were coated with 100 μl of recombinant human OX40-his at 2 μg / ml in PBS (see Example 1 for the production of OX40 -his protein). Plates were incubated overnight at 4°C and then blocked with PBS 2% BSA (Bovine Serum Albumine, PAA Laboratories, Pasching, Austria) for 1 hour at room temperature (RT). Blocking solution was removed and hybridoma supernatant or purified antibody was added. Plates were incubated at room temperature for 30 min and then washed with PBS 0.01% Tween-20 (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) and horseradish peroxidase (HRP)-labeled goat anti-mouse H+L-9 Second-rate. Detection antibodies (Sigma-Aldrich Chemie GmbH, B...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a new class of TNFR agonist comprising multiple binding portions to two different parts of the same TNFR. The present invention also relates to methods of activating components of the immune system in a patient via the administration of a TNFR agonist according to the present invention as well as the use of such materials for further therapeutic and other purposes.

Description

technical field [0001] The present invention relates to a new class of tumor necrosis factor receptor superfamily (TNFR) agonists comprising multiple binding moieties that bind to at least two different parts of TNFR. The invention also relates to methods of activating components of a patient's immune system by administering TNFR agonists according to the invention, and the use of these materials for therapeutic and other purposes. Background technique [0002] Immunotherapy has become a major focus of innovation in the development of anticancer therapies, because when successful patients have a durable antitumor immune response, not only the primary tumor but also metastatic lesions can be eradicated and can lead to the establishment of protective antitumor immune responses. Tumor memory immune response. Researchers have focused, and with great success, on therapies that neutralize checkpoint inhibitors, such as CTLA-4 and PD-1, that remove anti-tumor T cell responses in v...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28A61P37/04
CPCC07K16/2878C07K2317/24C07K2317/30C07K2317/33C07K2317/52C07K2317/55C07K2317/569C07K2317/622C07K2317/624C07K2317/64C07K2317/75C07K2317/92C07K2317/94A61P37/04A61K2039/505C07K2317/35C07K2317/567
Inventor S·布莱因F·卢梭R·利西拉J·拜克J·麦考因C·斯图茨
Owner ICHNOS SCI SA